Estimation of HCV-related morbidity and long-term mortality at the village cohort site

Beyond our analysis of HCV prevalence and incidence in Egypt, we considered important to collect data on HCV-related morbidity to measure the real burden of HCV-related disease and the needs for treatment. Our previous work showed that of 448 adults with HCV antibodies at the village of Zwyat Razin in 2002, 63.2% were chronically infected with HCV, 24.3% had elevated liver enzymes, 11.6% had liver enzymes >1.5 the ULN , and 4.4% had decompensated liver cirrhosis (Mohamed M.K. et al., J Med Virol, 2006). Unfortunately, in the absence of simple tools to measure liver fibrosis at that time, it has not been possible to estimate liver fibrosis distribution in the village population, the information most relevant for judging the severity of disease and treatment indications. We also documented that prior to learning their anti-HCV serological test results, participants with asymptomatic chronic HCV infection had no alteration in their quality of life compared to those without HCV infection (Schwarzinger et al., Hepatology, 2004). 


Thanks to a long-term follow-up of this cohort as well of two other similar cohorts located in the Nile Delta (Qaloubeya Governorate) and Upper Egypt (Assiut governorate), we will be able to make a comparison of the 9-year mortality among cohort participants who had chronic HCV (ELISA+, PCR+), past HCV (ELISA+, PCR-), and no HCV infection at study intake. Vital status (dead / alive) was assessed in 2008 among 16,282 study subjects (1,473 with chronic, 885 with past, and 13,924 with no infection) recruited between 1997 and 2002.


Note: This study has now been completed and results will be posted here soon


Back to Past Research


Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union